The American Journal of Managed Care2h
SGT-003 Gene Therapy Shows Potential in DMD
In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...
Nanoparticles deliver microRNAs to muscle stem cells for potential muscular dystrophy treatment
In an international collaboration, researchers have made an important breakthrough in the therapeutic delivery of microRNAs ...
FDA removes clinical hold on Entrada’s Duchenne therapy
Entrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
technologynetworks1d
FDA Removes Hold on Duchenne Muscular Dystrophy Drug
Following a more than two-year-long hold, Entrada Therapeutics can get its Duchenne muscular dystrophy candidate back on ...
The Pharma Letter1d
FDA lifts clinical hold on Entrada’s ENTR-601-44 study
The US Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase Ib multiple ascending dose (MAD) clinical study of ...
Nanowerk1d
Using nanoparticles to transport microRNAs against Muscular Dystrophy to muscle stem cells
The scientists demonstrate that it is possible to specifically deliver the treatment to the muscle stem cells, avoiding ...
Muscular Dystrophy News1d
ENTR-601-44 trial for DMD adults amenable to exon 44 skipping OK’d
The FDA has lifted its hold and has given Entrada Therapeutics permission to launch a Phase 1b clinical trial to test ...
Avidity Biosciences: Looks Tempting, But Wait For Interim Phase 3 Data
Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...
FierceBiotech2d
Entrada's 2-year ordeal ends as FDA lifts hold on DMD drug
Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
Entrada Therapeutics gains FDA clearance for its Phase 1b ELEVATE-44-102 study, evaluating ENTR-601-44 in adult Duchenne ...
Entrada Therapeutics, Inc.: Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...
Entrada Shares Climb After FDA Removes Hold on Muscular Dystrophy Treatment
Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...